HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Fraud Class Action
SAN FRANCISCO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Abbott Laboratories (NYSE: ABT) investors who suffered significant losses to submit your losses now .
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Fraud Class Action
SAN FRANCISCO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Abbott Laboratories (NYSE: ABT) investors who suffered significant losses to submit your losses now .